CD99 Modulates the Proteomic Landscape of Ewing Sarcoma Cells and Related Extracellular Vesicles

Ewing sarcoma (EWS) is an aggressive pediatric bone tumor characterized by unmet clinical needs and an incompletely understood epigenetic heterogeneity. Here, we considered CD99, a major surface molecule hallmark of EWS malignancy. Fluctuations in CD99 expression strongly impair cell dissemination, differentiation, and death. CD99 is also loaded within extracellular vesicles (EVs), and the delivery of CD99-positive or CD99-negative EVs dynamically exerts oncogenic or oncosuppressive functions to recipient cells, respectively. We undertook mass spectrometry and functional annotation analysis to investigate the consequences of CD99 silencing on the proteomic landscape of EWS cells and related EVs. Our data demonstrate that (i) the decrease in CD99 leads to major changes in the proteomic profile of EWS cells and EVs; (ii) intracellular and extracellular compartments display two distinct signatures of differentially expressed proteins; (iii) proteomic changes converge to the modulation of cell migration and immune-modulation biological processes; and (iv) CD99-silenced cells and related EVs are characterized by a migration-suppressive, pro-immunostimulatory proteomic profile. Overall, our data provide a novel source of CD99-associated protein biomarkers to be considered for further validation as mediators of EWS malignancy and as EWS disease liquid biopsy markers.

[1]  Christopher S. Hughes,et al.  Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Robin L. Jones,et al.  The proteomic landscape of soft tissue sarcomas , 2023, Nature communications.

[3]  L. Horvath,et al.  Quantitative proteomic studies addressing unmet clinical needs in sarcoma , 2023, Frontiers in Oncology.

[4]  Mihaela E. Sardiu,et al.  Identification of small extracellular vesicle protein biomarkers for pediatric Ewing Sarcoma , 2023, Frontiers in Molecular Biosciences.

[5]  A. Punetha,et al.  Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice , 2023, Proteomes.

[6]  N. Hinata,et al.  Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma , 2022, Frontiers in Oncology.

[7]  Huanhuan Zhang,et al.  Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells. , 2022, Free radical biology & medicine.

[8]  E. Lawlor,et al.  The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review , 2022, Frontiers in Oncology.

[9]  Nadezhda T. Doncheva,et al.  The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest , 2022, Nucleic Acids Res..

[10]  U. Dirksen,et al.  Small round cell sarcomas , 2022, Nature Reviews Disease Primers.

[11]  K. S. Hall,et al.  Small round cell sarcomas , 2022, Nature Reviews Disease Primers.

[12]  R. Tucker,et al.  Revisiting the Tenascins: Exploitable as Cancer Targets? , 2022, Frontiers in Oncology.

[13]  S. Furlan,et al.  EWS-FLI1 and HOXD13 control tumor cell plasticity in Ewing sarcoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Sharon,et al.  Biology of the Extracellular Proteasome , 2022, Biomolecules.

[15]  Zhe S Chen,et al.  Proteomics technologies for cancer liquid biopsies , 2022, Molecular Cancer.

[16]  N. Caplen,et al.  Comprehensive profiling of mRNA splicing indicates that GC content signals altered cassette exon inclusion in Ewing sarcoma , 2022, NAR cancer.

[17]  J. Lötvall,et al.  A brief history of nearly EV‐erything – The rise and rise of extracellular vesicles , 2021, Journal of extracellular vesicles.

[18]  M. Negrini,et al.  Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS–FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity , 2021, Molecular Cancer Therapeutics.

[19]  S. Lessnick,et al.  EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma , 2021, bioRxiv.

[20]  P. Sorensen,et al.  Extracellular Vesicles in Reprogramming of the Ewing Sarcoma Tumor Microenvironment , 2021, Frontiers in Cell and Developmental Biology.

[21]  K. Stegmaier,et al.  TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma , 2021, Cancer cell.

[22]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[23]  Martin J. Aryee,et al.  STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. , 2021, Cancer cell.

[24]  D. Surdez,et al.  STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma. , 2021, Cancer cell.

[25]  U. Dirksen,et al.  Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives , 2021, Journal of clinical medicine.

[26]  Yan Tao,et al.  Pan-cancer analysis identifies ITIH1 as a novel prognostic indicator for hepatocellular carcinoma , 2021, Aging.

[27]  P. Houghton,et al.  GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth , 2020, Cell reports.

[28]  V. Casolaro,et al.  Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients , 2020, International journal of molecular sciences.

[29]  K. Neville,et al.  Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers , 2020, Oncotarget.

[30]  Laura A. Banaszynski,et al.  The roles of histone variants in fine-tuning chromatin organization and function , 2020, Nature Reviews Molecular Cell Biology.

[31]  Andrei Zinovyev,et al.  Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution. , 2020, Cell reports.

[32]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[33]  Lei Li,et al.  EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma , 2019, British Journal of Cancer.

[34]  Michael Zhuo Wang,et al.  Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis , 2019, Cells.

[35]  M. Ferracin,et al.  Exosomes from CD99-deprived Ewing sarcoma cells reverse tumor malignancy by inhibiting cell migration and promoting neural differentiation , 2019, Cell Death & Disease.

[36]  Natalie S. Fox,et al.  The Proteogenomic Landscape of Curable Prostate Cancer. , 2019, Cancer cell.

[37]  E. Álava,et al.  Ewing sarcoma , 2018, Nature Reviews Disease Primers.

[38]  P. Lollini,et al.  Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 is a Novel Post-Transcriptional Regulator of Ewing Sarcoma Malignancy , 2018, Clinical Cancer Research.

[39]  K. Stegmaier,et al.  EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma , 2018, Nature.

[40]  K. Scotlandi,et al.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors , 2018, Genes.

[41]  W. Huber,et al.  Proteome-wide identification of ubiquitin interactions using UbIA-MS , 2018, Nature Protocols.

[42]  K. Scotlandi,et al.  CD99 at the crossroads of physiology and pathology , 2018, Journal of Cell Communication and Signaling.

[43]  H. Stark,et al.  Long-range allosteric regulation of the human 26S proteasome by 20S proteasome-targeting cancer drugs , 2017, Nature Communications.

[44]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[45]  U. Dirksen,et al.  Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells , 2017, Oncogene.

[46]  Nathan C. Sheffield,et al.  DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma , 2017, Nature Medicine.

[47]  C. Wetmore,et al.  Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma , 2017, Sarcoma.

[48]  F. Gosetti,et al.  The secretome signature of malignant mesothelioma cell lines. , 2016, Journal of proteomics.

[49]  B. Taylor,et al.  Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. , 2016, Cancer research.

[50]  A. Carè,et al.  CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-κB signaling , 2016, Oncogene.

[51]  M. Ricote,et al.  GOplot: an R package for visually combining expression data with functional analysis , 2015, Bioinform..

[52]  P. Sorensen,et al.  Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. , 2015, Cancer cell.

[53]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[54]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[55]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[56]  Philippe Bardou,et al.  jvenn: an interactive Venn diagram viewer , 2014, BMC Bioinformatics.

[57]  M. Fukuda,et al.  Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody , 2014, Clinical Cancer Research.

[58]  J. Hardes,et al.  Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals , 2014, Cancer Immunology, Immunotherapy.

[59]  P. Lollini,et al.  CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity , 2014, Oncogene.

[60]  P. Lollini,et al.  CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2 , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[61]  M. Stern,et al.  MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor , 2013, Oncogene.

[62]  M. Beckerle,et al.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. , 2012, Genes & cancer.

[63]  Annalisa Astolfi,et al.  CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. , 2010, The Journal of clinical investigation.

[64]  P. Fox,et al.  Spatial coordination of actin polymerization and ILK-Akt2 activity during endothelial cell migration. , 2009, Developmental cell.

[65]  S. Hirohashi,et al.  Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics , 2009, Clinical Cancer Research.

[66]  Martin Vingron,et al.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression , 2002, ISMB.

[67]  U. Weidle,et al.  The XAGE family of cancer/testis‐associated genes: Alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma , 2002, International journal of cancer.

[68]  I. Pastan,et al.  XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. , 2000, Cancer research.